Biologic Treatment Strategies for Chronic Rhinosinusitis

Abstract

Chronic rhinosinusitis (CRS) is a persistent inflammatory condition of the paranasal sinuses that imposes significant morbidity on affected individuals. Traditionally managed with medical therapies and surgery, the advent of biologic agents has transformed the therapeutic paradigm for refractory cases, especially those with type 2 inflammation. This review synthesizes current evidence on biologic treatment strategies for CRS, elucidates their mechanisms, clinical efficacy, and safety, and discusses guideline-driven recommendations for their use in clinical practice.

Introduction

Chronic rhinosinusitis, characterized by sinonasal inflammation persisting for more than 12 weeks, affects millions worldwide. The disease spectrum comprises CRS with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP). Conventional therapies, including corticosteroids, antibiotics, and surgical interventions, often provide suboptimal control in recalcitrant cases, leading to substantial healthcare utilization and reduced quality of life. Recent advances in the understanding of CRS pathophysiology have enabled the development of targeted biologic therapies, offering new hope for patients with severe disease. This article reviews the scientific basis, clinical application, and future prospects of biologic agents in CRS management.

Epidemiology / Disease Burden

CRS affects approximately 11–12% of the adult population globally, with notable geographical variation influenced by environmental and genetic factors. The disease is associated with significant direct and indirect costs, including frequent physician visits, medication expenses, absenteeism, and diminished work productivity. CRS with nasal polyps is particularly burdensome due to its chronicity, high recurrence rates, and association with comorbidities such as asthma and aspirin-exacerbated respiratory disease (AERD). The overall impact on patient-reported outcomes and quality of life underscores the need for more effective and durable treatments.

Pathophysiology

The pathogenesis of CRS is multifactorial, involving complex interactions between host immunity, environmental exposures, and microbial agents. A key distinction exists between type 2 (Th2-mediated) and non-type 2 (Th1/Th17-mediated) inflammatory endotypes. Type 2 inflammation, predominant in CRSwNP, is characterized by eosinophilic infiltration, elevated IgE, and increased cytokines such as IL-4, IL-5, and IL-13. These mediators drive tissue remodeling, polyp formation, and persistent mucosal inflammation. Non-type 2 endotypes, more common in CRSsNP, are less responsive to corticosteroids and lack targeted biologic options. Understanding these mechanisms has enabled the rational design of biologic therapies that interrupt specific inflammatory pathways.

Risk Factors

Risk factors for CRS include genetic predisposition, allergic rhinitis, asthma, smoking, environmental pollution, occupational exposures, and immune deficiencies. Patients with comorbid asthma or AERD often exhibit more severe, refractory disease with a type 2 inflammatory signature. Other contributory factors include anatomical variations, previous sinonasal surgery, and chronic infections. Identifying these risks is crucial for prognostication and tailoring individualized treatment plans.

Clinical Features

CRS presents with a constellation of symptoms, including nasal congestion, mucopurulent discharge, facial pain or pressure, and reduction or loss of smell. CRSwNP is specifically associated with visible nasal polyps on endoscopy and more pronounced olfactory dysfunction. The chronicity and severity of symptoms, resistance to standard therapies, and the impact on daily activities guide clinicians in assessing disease burden and treatment response. Objective findings on nasal endoscopy and radiographic imaging (e.g., CT scan) aid in confirming the diagnosis and evaluating anatomical contributors.

Diagnosis

The diagnosis of CRS is based on the presence of cardinal symptoms for at least 12 weeks, supported by objective evidence of mucosal inflammation on endoscopy or imaging. Nasal endoscopy enables direct visualization of polyps, mucosal edema, and purulent discharge. Computed tomography (CT) of the sinuses reveals the extent and distribution of sinus opacification, bony changes, and anatomical variations. Laboratory tests, including allergy panels and immunologic workup, may be warranted in select cases. Emerging biomarkers, such as periostin and eosinophil counts, are being investigated for their utility in endotyping and predicting biologic treatment response.

Treatment & Management

Standard management of CRS involves intranasal corticosteroids, saline irrigation, short courses of oral corticosteroids, and, when indicated, antibiotics for acute exacerbations. Endoscopic sinus surgery is reserved for patients with obstructive disease or those refractory to maximal medical therapy. Despite these interventions, a subset of patients experiences persistent symptoms due to underlying type 2 inflammation. In this context, biologic agents targeting key cytokines and immunoglobulins have emerged as adjunctive or alternative therapies, particularly for CRSwNP with comorbid asthma or AERD.

Recent Advances / Emerging Therapies

The introduction of biologics marks a pivotal shift in CRS therapeutics. Agents such as dupilumab (anti-IL-4Rα), omalizumab (anti-IgE), and mepolizumab (anti-IL-5) have demonstrated significant efficacy in randomized controlled trials for CRSwNP. Dupilumab, by inhibiting IL-4 and IL-13 signaling, reduces polyp size, improves nasal airflow, and enhances quality of life. Omalizumab decreases IgE-mediated inflammation, while mepolizumab targets eosinophilic pathways central to polypogenesis. These agents are generally well-tolerated, with injection site reactions and transient eosinophilia being the most common adverse events. Ongoing studies are evaluating novel targets, such as IL-33 and TSLP, and expanding indications to difficult-to-treat CRSsNP subgroups.

Guideline Recommendations

International consensus guidelines, including those from the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) and the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), endorse the use of biologics for severe, refractory CRSwNP with evidence of type 2 inflammation. Selection criteria typically include prior failure of standard therapies, recurrent polyps post-surgery, and significant impact on quality of life. Shared decision-making, assessment of comorbidities, and regular monitoring are emphasized to optimize outcomes and minimize risks. Cost-effectiveness and long-term safety remain key considerations in clinical practice.

Conclusion

The emergence of biologic therapies represents a major advancement in the management of chronic rhinosinusitis, particularly for patients with recalcitrant CRSwNP driven by type 2 inflammation. These agents offer targeted, mechanism-based interventions that address the underlying immunopathology, leading to substantial improvements in symptoms and quality of life. Ongoing research will further refine patient selection, duration of therapy, and integration with existing treatment algorithms. As clinical experience with biologics expands, they are poised to become a cornerstone of personalized care for CRS.